0000000000811047

AUTHOR

Marie Boyle

showing 2 related works from this author

Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.

2019

Background & Aim There is an unmet need for non-invasive biomarkers in non-alcoholic fatty liver disease (NAFLD) that can diagnose advanced disease and identify patients suitable for clinical trials. The PRO-C3 collagen neo-epitope is a putative direct marker of fibrogenesis. We assessed the performance of PRO-C3 in a large, well-characterised international NAFLD cohort and report the development and validation of 2 novel panels for the diagnosis of advanced fibrosis (F≥3) in NAFLD, including a simplified clinical score which eliminates the need for online calculators. Methods Plasma PRO-C3 levels were determined in a prospectively recruited international cohort of 449 patients with biopsy …

medicine.medical_specialtyADVANCED FIBROSISSCORING SYSTEMPROGRESSIONGastroenterologySTEATOHEPATITIS03 medical and health sciences0302 clinical medicineFibrosisInternal medicineNAFLDBiopsyInternal MedicineImmunology and AllergyMedicineSTEATOSISPRO-C3Stage (cooking)lcsh:RC799-869030304 developmental biologySteatohepatitisRISK0303 health sciencesScience & TechnologyHepatologymedicine.diagnostic_testGastroenterology & Hepatologybusiness.industryFatty liverfibrosisGastroenterologyNASHDIABETES-MELLITUSCHRONIC HEPATITISBiomarkermedicine.disease3. Good healthClinical trialCohortBIOPSYBiomarker (medicine)030211 gastroenterology & hepatologylcsh:Diseases of the digestive system. GastroenterologySteatohepatitisbusinessLife Sciences & BiomedicineResearch ArticleJHEP reports : innovation in hepatology
researchProduct

Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation

2019

Background & Aims Chronic liver disease has negative effects on health-related quality of life (HRQL). We analyzed data from the European non-alcoholic fatty liver disease (NAFLD) registry to assess the effects of NAFLD on HRQL. Methods We collected data from 304 patients (mean age, 52.3 ± 12.9 years) with histologically defined NAFLD enrolled prospectively into the European NAFLD Registry in Germany, the United Kingdom, and Spain. The chronic liver disease questionnaire (CLDQ) was completed within 6 months of liver biopsy collection. Results The mean CLDQ overall score was 5.0 ± 1.2, with the lowest score in the category fatigue (4.3 ± 1.6) and the highest scores for activity (5.4 ± 1.4). …

medicine.medical_specialtyCirrhosisHepatologymedicine.diagnostic_testbusiness.industryFatty liverGastroenterologymedicine.diseaseChronic liver diseaseGastroenterology3. Good health03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisDiabetes mellitusLiver biopsyInternal medicineNonalcoholic fatty liver diseasemedicine030211 gastroenterology & hepatologyPatient-reported outcomebusinessBody mass indexClinical Gastroenterology and Hepatology
researchProduct